CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions

[Display omitted] Triple negative breast cancer (TNBC) has been well-known to be closely associated with the abnormal expression of both oncogenes and tumor suppressors. Although several pathogenic mutations in TNBC have been identified, the current therapeutic strategy is usually aimed at symptom r...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2023-03, Vol.209, p.115449-115449, Article 115449
Main Authors: Fu, Leilei, Li, Zixiang, Ren, Yueting, Yu, Haiyang, Liu, Bo, Qiu, Yuling
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapy
CRISPR-Cas Systems
CRISPR/Cas
Gene Editing
Humans
Triple negative breast cancer
Triple Negative Breast Neoplasms - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Triple negative breast cancer (TNBC) has been well-known to be closely associated with the abnormal expression of both oncogenes and tumor suppressors. Although several pathogenic mutations in TNBC have been identified, the current therapeutic strategy is usually aimed at symptom relief rather than correcting mutations in the DNA sequence. Of note, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) has been gradually regarded as a breakthrough gene-editing tool with potential therapeutic applications in human cancers, including TNBC. Thus, in this review, we focus on summarizing the molecular subtypes of TNBC, as well as the CRISPR system and its potential applications in TNBC treatment. Moreover, we further discuss several emerging strategies for utilizing the CRISPR/Cas system to aid in the precise diagnosis of TNBC, as well as the limitations of the CRISPR/Cas system. Taken together, these findings would demonstrate that CRISPR/Cas system is not only an effective genome editing tool in TNBC, but a promising strategy for the future therapeutic purposes.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2023.115449